Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market - 2022-2029

Market Overview

Non-alcoholic steatohepatitis therapeutics and diagnostics market was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 22.31% during the forecast period (2022-2029).

Non-alcoholic steatohepatitis (NASH) is a common cause of chronic liver disease strongly associated with insulin resistance leading to fibrosis. Type 2 diabetes and NAFLD commonly exist together. NAFLD comprises simple steatosis (NAFL), non-alcoholic steatohepatitis, and cirrhosis. According to the National Institute of Health, in 2021, Type 2 diabetes results from the body's ineffective use of insulin. In year 2021 more than 95% of people with diabetes have type 2 diabetes. Hence the rising incidence and prevalence rate of diabetes creates significant scope for the non-alcoholic steatohepatitis therapeutics and diagnostics market. The rising prevalence of non-alcoholic steatohepatitis and the high prevalence of liver-related diseases are some factors that are expected to propel market growth.

Market Dynamics: Research for non-alcoholic steatohepatitis biomarkers will continue supporting the growth of the market during the forecast period

Increasing research activities to raise the already available biomarkers' productivity and efficiency or discover new ones is expected to create enormous opportunities for growth in the non-alcoholic steatohepatitis market. The prevalence of non-alcoholic steatohepatitis across the globe is increasing dramatically, driving the requirement for various diagnosis methods. The current method for the diagnosis of non-alcoholic steatohepatitis includes live biopsy, which is an invasive procedure. Although liver biopsy is still considered the most reliable standard for diagnosing non-alcoholic steatohepatitis, it can lead to various clinical complications such as trauma and bleeding.

Also, government support through programs and initiatives is driving the growth of the global market. Organizations' increasing number of programs and initiatives to develop non-alcoholic steatohepatitis drugs and diagnostic tools significantly drives the market's growth. For instance, in 2021, Global liver institute released U.S. NASH action plan. This plan included updated guidelines for standards of care and coordinated care pathways, adoption and reimbursement of non-invasive diagnostics, Payor and health system research on patient-centric value-based care and benefit design and Integration of NASH into public health, regulatory, and legislative priorities.

Market Segmentation: The diagnostic tests segment accounted for the highest share in global non-alcoholic steatohepatitis therapeutics and diagnostics market

Only a few diagnostic tests are available to diagnose non-alcoholic steatohepatitis, including liver function tests, lipid profile tests, and fibrosis assessment tests. The presence of non-alcoholic steatohepatitis is confirmed when the diagnostic results of the tissue show fat, inflammation, and damage to liver cells. Moreover, several in-vitro diagnostics tests set to be released in 2021 will support segmental growth worldwide. Therefore, diagnostic tests contribute a major share in the growth of the global non-alcoholic steatohepatitis therapeutics and diagnostics market.

Based on the therapeutics, the non-alcoholic steatohepatitis therapeutics and diagnostics market has been classified into Ocaliva, Elafibranor, Cenicriviroc, Selonsertib, and others. Moreover, the Selonsertib segment held a significant share of market growth. Selonsertib for patients with linking fibrosis or compensated cirrhosis due to non-alcoholic steatohepatitis. It is an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), likely anti-inflammatory, antineoplastic, and anti-fibrotic activities. Selonsertib targets and ties to the catalytic kinase domain of ASK1 in an ATP-competitive approach; by this means, preventing its phosphorylation and activation. Therefore, Selonsertib contributes a considerable share to the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market across the globe.

Geographical Penetration: North America is the dominating region during the forecast period

North America dominated the global non-alcoholic steatohepatitis therapeutics and diagnostics market and is expected to retain its position during the forecast period. The US contributed the largest share in the North American non-alcoholic steatohepatitis therapeutics and diagnostics market in the forecast period. The primary factor contributing to the market's growth includes the significant funding provided by government organizations and pharmaceutical companies for the R&D of biomarkers. The presence of sophisticated healthcare amenities and the growing incidence of diabetes, obesity, and fatty liver disease support this region's target market's growth.

The Asia Pacific is estimated to grow at a considerable growth rate in the non-alcoholic steatohepatitis therapeutics and diagnostics market during the forecast period. The growth of Asia-Pacific is mainly attributed to the rapidly evolving healthcare infrastructure and increasing awareness of chronic liver conditions. Moreover, the expansion of foreign market players in the nation's emerging economies, such as China and India.

Competitive Landscape:

The non-alcoholic steatohepatitis therapeutics and diagnostics market is highly competitive. The key non-alcoholic steatohepatitis therapeutics and diagnostics players contributing to the global market's growth include Abbvie Inc., Cadila Healthcare Limited, Genfit SA, Gilead Sciences Inc., Novo Nordisk A/S, Quest Diagnostics, Shire Plc, Siemens Healthineers, Thermo Fisher Scientific Inc. The major players are adopting new product launches and expansion strategies for global growth in the non-alcoholic steatohepatitis therapeutics and diagnostics market. In February 2020, Meridian Bioscience signed a definitive agreement to acquired exalenz bioscience. The value of the acquisition of these two companies is around $49 million. By this acquisition, Meridian will be adding Exalenz's flagship BreathID Breath Test Systems, a urea breath test platform for detecting Helicobacter pylori, often associated with peptic ulcers and gastric ulcers cancer. BreathID furthers Meridian's strategy to be the leading provider of gastrointestinal diagnostic solutions. The platform offers patient-friendly, noninvasive sample collection and best-in-class sensitivity and specificity for adult and pediatric patients. Also, in December 2021, Thermo Fisher Scientific Inc. announced that it had completed its acquisition of PPD, Inc., a global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. PPD provided services to the biotech and biopharma industries.

COVID-19 Impact: Negative impact on the global non-alcoholic steatohepatitis therapeutics and diagnostics market

The COVID-19 pandemic has hampered the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market. Though the risk for the occurrence of COVID-19 is considerably high in patients suffering from non-alcoholic steatohepatitis, the new diagnosis and treatments have declined amidst the crisis. Moreover, the ongoing research in research institutes and other private organizations has been reduced due to a diversion in the R&D of the COVID-19 vaccine. Therefore, the demand for non-alcoholic steatohepatitis therapeutics and diagnostics is expected to decrease market value growth in 2020.

The global non-alcoholic steatohepatitis therapeutics and diagnostics market report would provide an access to approximately 76 market data tables, 60 figures and 170 pages